Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Autor: Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)

Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS

Externí odkaz: https://doaj.org/article/193c505adea04fdda590997c6e7e69c0

1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)

Autor: H-D. Hummel, B. Jaeschke, Martina Jänicke, Michael Thomas, J. Schröder, Martin Sebastian, A. Groth, Stefan Zacharias, C. Wesseler, Frank Griesinger, V. Petersen, C. Schumann, J. Wilke, S. Dörfel, A. Fleitz, A. Hipper, W. Eberhardt, Wilko Weichert, W. M. Brückl, Jens Kern

Publikováno v: Annals of Oncology. 32:S1015-S1016

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::388814f138a4972af9ba51ece20eecd9
https://doi.org/10.1016/j.annonc.2021.08.1926

Radiometric Calibration of a UAV-Mounted Hyperspectral Snapshot Camera with Focus on Uniform Spectral Sampling

Autor: Andreas Schenk, Jens Kern, Stefan Hinz

Publikováno v: WHISPERS

Small and lightweight hyperspectral cameras mounted on unmanned aerial systems (UAS) are increasingly used as close range remote sensing systems. When they are applied to studies of biophysical parameters in environmental sciences, user have to consi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8991a4df9ec836d89657a1b5347811e9
https://doi.org/10.1109/whispers.2018.8747027

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the SCLC cohort

Autor: Peter Brossart, Walburga Engel-Riedel, Karl-Otto Kambartel, Christian Grohé, Andreas H. Scheel, Frank Griesinger, Barbara Hermes, Rieke Fischer, Jens Panse, Martin Sebastian, Hans Anton Schloesser, Rainer Wiewrodt, Juergen Wolf, Maria J G T Vehreschild, Markus Lehmann, Reinhard Büttner, Kathrin Nachtkamp, Roman K. Thomas, Jens Kern, Julie George

Publikováno v: Journal of Clinical Oncology. 37:8563-8563

e20550 Background: Patient selection, dosing regimens and resistance mechanisms for immune checkpoint inhibitor combination therapy remain unmet medical needs in lung cancer. Combining blockade of PD-1 and CTLA-4 can be more effective than monotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163f8c016a79a7e0cd6ac9ee174958cf
https://doi.org/10.1200/jco.2019.37.15_suppl.8563

Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations

Autor: Juergen Wolf, Rieke Fischer, Anna Kron, Karl-Otto Kambartel, Joachim Lorenz, Matthias Scheffler, Lucia Nogova, Sabine Merkelbach-Bruse, Sebastian Michels, Britta Kaminsky, Reinhard Büttner, Claudia Wompner, Michaela Angelika Ihle, Elisabeth Bitter, Ulrich Gerigk, Alessandra Holzem, Winfried Randerath, Jens Kern

Publikováno v: Journal of Clinical Oncology. 35:e20059-e20059

e20059 Background: MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive with known driver mutations. Activation of the MEK1-cascade might play a pivotal role in resistance to targeted inhibition of B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3123d9d87a2690243921a66796da7356
https://doi.org/10.1200/jco.2017.35.15_suppl.e20059